Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
eMedI Chat: Medical Information Database
Find Your Medical Representative
Long-term effectiveness and safety of avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: updated systematic literature review and meta-analysis
Barthélémy | 678-D2
Real-world first-line treatment patterns and overall survival in patients with locally advanced/metastatic urothelial carcinoma and frailty or comorbidities
Grande | 666-C16
Avelumab in combination with other anticancer agents as first-line maintenance treatment for advanced urothelial carcinoma: primary analysis from the JAVELIN Bladder Medley phase 2 trial
Hoffman-Censits | 739-F11
Clinical outcomes in patients with locally advanced or metastatic urothelial cancer in France treated with avelumab first-line maintenance: a real-world observational study using the French National Healthcare Database (Système National des Données de Santé [SNDS])
Houede | 740-F12
Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: longterm follow-up from the JAVEMACS chart review study
Kobayashi | 674-C24
Real-world effectiveness and safety of first-line avelumab + axitinib in patients with advanced renal cell carcinoma: final analysis of the prospective AVION study
Merseburger | 438-A26
Healthcare resource utilization and costs among US patients with locally advanced or metastatic urothelial cancer treated with first-line treatment regimens: results from the ELEVATE UC-I study
Nizam | 871-L25
Real-world safety of first-line systemic regimens for locally advanced or metastatic urothelial cancer: updated results from the ELEVATE UC-I study
Nizam | 680-D4
Characteristics, treatment patterns, and outcomes in patients with locally advanced or metastatic urothelial cancer: a retrospective observational study in England
Stevenson | 665-C15
Efficacy and safety of avelumab + axitinib vs sunitinib in patients with very favorable–risk advanced renal cell carcinoma (aRCC): subgroup analysis from the JAVELIN Renal 101 trial
Venugopal | 560-F18
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00046 1/26
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
Welcome to EMD Serono Medical Information!
Help us direct you to the right information by selecting one of the following options:






